Effects of Leuprorelin in Post-Menopausal Breast Cancer
Author Information
Author(s): I.L. Crighton, M. Dowsett, A. Lal, A. Man, I.E. Smith
Primary Institution: Royal Marsden Hospital
Hypothesis
Can leuprorelin effectively treat advanced post-menopausal breast cancer?
Conclusion
Leuprorelin was largely ineffective as a single agent therapy for post-menopausal breast cancer, although it did lower testosterone levels in most patients.
Supporting Evidence
- None of the 15 patients showed an objective response to treatment.
- Four patients had stable disease for at least 6 months.
- Mean serum testosterone levels fell significantly during treatment.
Takeaway
The study tested a drug called leuprorelin on women with advanced breast cancer, but it didn't help most of them, even though it lowered some hormone levels.
Methodology
Fifteen post-menopausal women with advanced breast cancer were treated with leuprorelin and monitored for clinical and endocrine responses.
Limitations
The study had a small sample size and did not include a control group.
Participant Demographics
Mean age was 66 years, all participants were post-menopausal, with varying previous treatments.
Statistical Information
P-Value
p<0.002
Confidence Interval
95% confidence limits
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website